纯膜性狼疮肾炎与增殖性狼疮肾炎患者短期和长期结局比较
纳入215例首次活检证实的纯膜性狼疮肾炎(51例)与增殖性狼疮肾炎(164例)患者,比较1年和2年完全蛋白尿恢复、完全肾脏缓解和主要疗效肾脏缓解,两组均无显著差异。长期结局方面,增殖性狼疮肾炎与更差的肾脏及非肾脏结局相关,但未达统计学显著。多变量Cox模型显示,终末期肾病与较年轻年龄、较高肌酐、低补体和较高慢性化指数相关。
要点
- 纯膜性狼疮肾炎与增殖性狼疮肾炎在1年和2年的完全蛋白尿恢复、完全肾脏缓解和主要疗效肾脏缓解上无显著差异。
- 增殖性狼疮肾炎与更差的长期肾脏及非肾脏结局相关,但未达统计学显著。
- 终末期肾病与较年轻年龄、较高肌酐、低补体和较高慢性化指数相关。
核心结论
- 狼疮肾炎中蛋白尿消退缓慢。
- 纯膜性狼疮肾炎并非良性疾病,可能与肾功能恶化、终末期肾病、损伤、心血管事件和死亡相关。
研究设计与样本
- 纳入首次活检证实的纯膜性狼疮肾炎和增殖性狼疮肾炎患者,纯膜性狼疮肾炎51例,增殖性狼疮肾炎164例,共215例。
- 短期结局包括完全蛋白尿恢复(CPR)、完全肾脏缓解(CRR)和主要疗效肾脏缓解(PERR)。
- 长期结局包括基线估算肾小球滤过率持续下降≥40%、终末期肾病(ESKD)、心血管(CV)事件、SLICC/ACR损伤指数增加≥2和死亡。
- 采用单变量和多变量Cox比例风险模型检验基线特征对长期结局的影响。
主要发现
- 两组在1年和2年达到完全蛋白尿恢复、完全肾脏缓解和主要疗效肾脏缓解方面无显著差异。
- 纯膜性狼疮肾炎组达到结局的中位时间略长于增殖性狼疮肾炎组,但差异无统计学意义。
- 增殖性狼疮肾炎与更差的肾脏和非肾脏结局相关,但未达统计学显著。
- 多变量Cox比例风险模型中,终末期肾病与较年轻年龄(HR 0.92,95%CI 0.87-0.97)、较高肌酐(HR 1.01,95%CI 1.01-1.02)、低补体(HR 4.0,95%CI 1.04-11.10)和较高慢性化指数(HR 1.28,95%CI 1.08-1.51)相关。
关键数值与推荐
- 完全蛋白尿恢复、完全肾脏缓解和主要疗效肾脏缓解在1年和2年两组间均无显著差异。
- 终末期肾病与较年轻年龄相关(HR 0.92,95%CI 0.87-0.97)。
- 终末期肾病与较高肌酐相关(HR 1.01,95%CI 1.01-1.02)。
- 终末期肾病与低补体相关(HR 4.0,95%CI 1.04-11.10)。
- 终末期肾病与较高慢性化指数相关(HR 1.28,95%CI 1.08-1.51)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Membranous LN (MLN) is thought to have a more benign course than proliferative LN (PLN). We aimed to determine the differences in short- and long-term outcomes between patients with MLN and PLN. METHODS: We included patients with first biopsy-proven MLN and PLN. Short-term outcomes included complete proteinuria recovery (CPR), complete renal response (CRR) and primary efficacy renal response (PERR). Long-term outcomes included a sustained ≥40% reduction in baseline estimated glomerular filtration rate, end-stage kidney disease (ESKD), cardiovascular (CV) events, ≥2 increase in SLICC/ACR Damage Index and death. Univariable and multivariable Cox proportional hazard models were used to examine the effect of baseline characteristics on long-term outcomes. RESULTS: Of 215 patients, 51 had pure MLN and 164 had PLN. We found no significant differences between the two groups in achieving CPR, CRR and PERR at 1 and 2 years. Median time to outcomes was slightly, but insignificantly, longer in the MLN group. For long-term outcomes, PLN was associated with worse renal and non-renal outcomes, but this was not statistically significant. In the multivariable Cox proportional hazard models, ESKD was associated with the following baseline variables: younger age [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.87-0.97], higher creatinine (HR 1.01, 95% CI 1.01-1.02), low complement (HR 4.0, 95% CI 1.04-11.10) and higher chronicity index (HR 1.28, 95% CI 1.08-1.51). CONCLUSION: The resolution of proteinuria in LN is slow. MLN is not a benign disease and may be associated with deterioration of renal function, ESKD, damage, CV events and death.
引用
- Kharouf F, Li Q, Whittall Garcia LP, et al. Short- and long-term outcomes of patients with pure membranous lupus nephritis compared with patients with proliferative disease. Rheumatology (Oxford). 2025. PMID: 39133193. doi:10.1093/rheumatology/keae436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。